INFORMACIÓN BÁSICA SOBRE COOKIES

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web.
La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias.
Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso.
En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web.
Más información en el apartado POLÍTICA DE COOKIES de nuestra página web.

ACEPTAR RECHAZAR
  • Tel. 900 101 549
  • +34 93 546 01 35
  • Facebook IOR
  • Twitter IOR
  • LinkedIn IOR
  • Hospital Universitari Dexeus
  • Centro Médico Teknon
  • Hospital Universitari General de Cataluña
  • Hospital Universitari Sagrat Cor

LINES OF INVESTIGATION


THE IMPORTANCE of ongoing investigation
Our Molecular Oncology Laboratory runs innovative translational cancer research programs with the goal of generating a new framework of cancer therapy based on personalized diagnostic models, and incorporating this strategy into daily clinical practice.
 
R+D Biomarker Discovery
Our aim is to elucidate the role genes play in cancer development and use this knowledge to improve patient care by identifying novel theranostic biomarkers. We focus on validation of new gene signatures predictive of response to adjuvant and neoadjuvant treatment.
 

R+D Diagnostics
Our innovative R+D Diagnostics program focuses on the development of novel molecular diagnostic tools specifically designed to detect biomarkers in clinical use. Using standard techniques, we focus on development of new assays to detect validated biomarkers such as EGFR, ALK, ROS, BRCA1, BRAF and others.
 
‘Liquid Biopsy’ Program
We are leaders in the field of non-invasive diagnostic tests using alternative biosources such as cerebrospinal fluid or serum, plasma and platelets from blood samples. In certain types of cancer such as lung cancer, insufficient tumor tissue obtained by traditional biopsy can mean it is not possible to perform vital diagnostic tests. Our blood tests not only overcome this difficulty, but also permit real time monitoring of the disease and early detection of resistance. Our assays have the required sensitivity and specificity for immediate incorporation into clinical practice.

As an example of our capabilities in this field, we have developed highly sensitive and specific techniques with clinical applications for the detection of genetic alterations in blood of lung cancer patients.